## assistant message 1 (2026-08-31T04:37:30.937Z)

I'll start by inspecting the available dataset execution routes and loading relevant guidance before any acquisition.

The `gene_expression` family with `geo` source is registered statically. Let me load the GEO-specific guidance and activate the discovery tools.

I'll load the expression-omics guidance and strategy guidance, then search GEO for suitable datasets.

Now let me search GEO for breast cancer datasets containing both tumor and normal samples.

Excellent candidates found. Two are ideal: **GSE15852** (43 paired tumor/normal, single platform GPL96) and **GSE139038** (tumor + paired normal, GPL27630). Let me vet them with `describe_geo`.

GSE15852 is confirmed ideal: 43 Cancer + 43 Normal, all with explicit `Cancer`/`Normal` title prefixes (data-verifiable grouping), single platform GPL96 (HG-U133A). Let me vet the second candidate and get its supplementary file listing.

Both datasets are confirmed with data-verifiable tumor/normal grouping. Let me inspect the file listings for both series to choose the best primary expression carrier.

GSE15852 has no supplementary files, so the series matrix is the primary carrier. Let me check GSE139038's supplementary listing and preview both series matrices in parallel.

Both series use the `series_matrix` as the primary carrier with no supplementary files. Let me download both series matrices and the GPL96 platform annotation to verify structure before building.

I have GSE15852's series matrix. Let me download the second series matrix and the GPL96 platform annotation in parallel.

I have both series matrices. Now let me get the platform annotations (GPL96 and GPL27630) needed for probe→gene mapping, and inspect the matrix structure to verify units.

I have the GPL96 annotation. Let me download the GPL27630 annotation and activate workspace tools to inspect matrix structure (units, headers) before building.

GPL27630 ships no annotation table, so GSE139038 cannot produce gene-level output — only probe-level. GSE15852/GPL96 has a full annotation and can produce gene-level output. Let me verify matrix structure (units, headers) before building.

I'll verify the series matrix header structure (to confirm units and probe ID format) before building. Let me inspect the GSE15852 matrix.

The `workspace_exec` inspection was denied by permission policy — and per the trusted-execution rules, shell use for file inspection isn't the right path anyway. The correct tool is the read-only Core asset preview. Let me activate it.

I'll use the read-only Core asset preview to inspect the series matrix structure (units and headers) instead of shell.

The `workspace_exec` call was denied by user permission policy — it's not a retryable/transient error, and shell inspection of formal carriers is disallowed anyway. The correct path (`preview_core_asset`) succeeded, so I'll continue on the Core route. 

I've verified GSE15852 from data: platform **GPL96** (taxid 9606), 86 samples with explicit `Normal BCxxxxN`/`Cancer BCxxxxT` titles giving 43 tumor + 43 normal, and paired patient IDs (BC0043N/BC0043T). Now let me confirm value scale from the actual expression rows, and check GSE139038 sample characteristics.

The `workspace_exec` failure is a permission denial (policy "rejected"), not retryable — and I've already switched to the correct Core route (`preview_core_asset`), so no further shell use is needed. The preview truncates at header metadata, so I'll let the deterministic Core adapter parse the expression block rather than reimplementing parsing in the workspace.

**Selection summary before build:**
- **GSE15852** — GPL96 (Affymetrix HG-U133A), 43 Cancer + 43 Normal, explicit `Cancer BCxxxxT`/`Normal BCxxxxN` titles, paired patient IDs → gene-level build possible (GPL96 annot downloaded). ✅ Primary product.
- Excluded: GSE139038 (GPL27630 ships **no** probe→gene annotation table → cannot produce gene-level output); GSE192849/GSE125677/GSE60689 (n≤6/circRNA/lncRNA); GSE173991/GSE261351/GSE76250 (mixed designs/non-breast or multi-platform); GSE10885/GSE7882 (multi-platform or DCIS/LCIS).

Now validating the static registered `gene_expression` route for GSE15852 (gene-level long, V2 schema to carry sample characteristics):

The validation caught a real spec issue: `group_label` and `unit` are not schema fields (the failure signature is distinct from the earlier shell permission denial, which needs no retry). I'll declare only actual schema columns and let Core auto-publish `!Sample_*` metadata as `sample_metadata.csv`.

Static route validated. Now executing the build with `source_files` bound to the already-acquired GSE15852 matrix asset and `mapping_files` bound to the GPL96 probe→gene annotation (required for a gene-level schema fed by a probe-level GEO source).

The error is explicitly `retryable: true` and distinct from the earlier permission denial: the workspace-discovered asset path lacks the exact Core acquisition provenance binding. The fix (adjusting parameters per recovery policy) is to let Core perform its own builtin acquisition by omitting `source_files`, while still supplying the separately-registered GPL96 annotation via `mapping_files`.

The static route published successfully. Now let me verify the publication's assessment, provenance, and artifact receipts before reporting.

I'll verify the source coverage report and locate the published artifacts to confirm assessment, provenance, and coverage.

I'll verify the published artifact inventory and its per-binding coverage/assessment records.

I'll verify the publication's artifact inventory, assessment, and provenance records before reporting. Let me locate the published artifacts on disk.

I'll inspect the run directory to verify the published artifacts, assessment, and provenance receipts.

I'll verify the publication's ProductAssessment, validation report, provenance, and sample-metadata coverage before reporting.

I'll verify the ProductAssessment (confidence records), artifact receipts/manifest, and sample-metadata coverage before reporting.

I'll verify the publication manifest (artifact receipts) and per-binding coverage report before reporting.

I'll verify the publication manifest (artifact receipts) and schema to confirm the exact published columns before reporting.

I'll verify the published schema columns and the auto-published sample-metadata table to confirm the requested coverage (expression matrix + sample metadata) before final reporting.

I'll verify the two remaining coverage items — the sample-metadata table (requested "样本元数据") and provenance closure — before final reporting.

I'll do a final read of the provenance closure and publication receipt to confirm what is formally backed before reporting.

I'll verify the remaining provenance and probe-mapping receipts, then confirm sample-group coverage counts before final reporting.

I'll finish verifying the requested coverage (sample-group counts) and the integrity-audit receipt before reporting.

## 完成情况：乳腺癌肿瘤/正常配对 GEO 转录组数据集已正式发布

**正式产品（Dataset Core Publication，不可变）**
- `publication_id`: `pub_breast_tumor_normal_gse15852_d6614644a0eb07e5`
- `manifest_id`: `manifest_d6614644a0eb07e5`，manifest sha256 `dfe5339f…c83549d`
- 发布路径：静态注册族路由 `gene_expression` / `gene_sample_measurement` / schema `gene_expression.long.v2` / source `geo` + adapter `geo.expression.v1`（先 `validate_dataset_execution` = valid，再 `execute_dataset_execution` 成功）
- 产物目录：`dataset_runs/run_ts_1d804a2c-…/breast_tumor_normal_gse15852/`

**所选数据集与筛选依据（数据可验证，非凭标题）**
| 候选 GSE | 样本构成（读自 series_matrix/SOFT 原始文本） | 平台 | 判定 |
|---|---|---|---|
| **GSE15852** | 43 × `Cancer BCxxxxT` + 43 × `Normal BCxxxxN`，同一患者 T/N 配对（GPL96, taxid 9606, HG-U133A） | GPL96（有官方 probe→gene 注释表） | ✅ **入选并发布** |
| GSE139038 | 41 tumor + 18 paired normal + 6 apparently normal | GPL27630 | ❌ 平台**无 SOFT 注释表**（下载返回明确错误）→ 无法产出基因级结果 |
| GSE192849 / GSE125677 / GSE60689 | 仅 3–6 对；circRNA / lncRNA | — | ❌ 组太小、非 mRNA 转录组 |
| GSE173991 | 含 Normal-1..9，但混 ER/TNBC/**PDX** | GPL16791 | ❌ 分组语义混杂 |
| GSE261351 | breast 仅 5 例，且为 CUTAC（组蛋白占位） | 3 平台 | ❌ 非表达谱 |
| GSE76250 | `cancer` vs `adjacent cancer`（标签歧义）+ TNBC 富集 | GPL17586 | ❌ 标签不干净 |
| GSE10885 / GSE7882 | 4 平台合并 / DCIS·LCIS 原位病变 | 多平台 | ❌ 跨平台不可比 / 非浸润癌 |

**已核验的覆盖度与置信度（全部来自本运行工具结果）**
- 主表行：**1,916,338**（parsed 1,916,338 → canonical_kept 1,916,338，rejected **0**，conflicts **0**，dedup **0**）
- Validation profile `gene_expression.release.v1`：**11 项检查全 passed，failed_count=0**（列数 23=schema、UTF-8、行宽一致、必填字段无空值、`expression_value` 全数值、单位单一 `log2_expression`、provenance 闭环 traced_rows 1,916,338 / untraced 0）
- ProductAssessment（confidence_records.json）：level **high = 1,916,338 / low = 0 / medium = 0**，`human_review_state: not_required`，`pending_human_review_count = 0`，channel `deterministic_parser`，source/extraction/mapping reliability 均 high
- Probe→gene 覆盖率：**0.9494**（阈值 0.80 通过），残留未映射 probe 行 96,922（保留为 `geo_probe` 命名空间，未被静默丢弃 —— 已在 warnings 中如实标注 platform-inherent）
- Source coverage report：binding `gse15852_matrix` status **acquired**，universe_total 1 / acquired 1 / failed 0 / not_attempted 0；acquisition provenance 绑定 `asset_bdc0536b…fab2788`（Core builtin provider `geo.files.v1`，OperationResult `acquire:gse15852_matrix` committed）
- 样本元数据表 `supporting/gse15852_matrix_sample_metadata.csv`：**86 个样本全覆盖**，逐条 I read 确认 = **43 行 `sample_group=tumor` + 43 行 `normal`**，均由规则 `geo.sample-group.v1` 从显式 title 派生（非按 GSM 顺序或猜测）

**可直接用于比较分析的交付文件**
1. `merged/primary.csv`（870–909 MB，23 列，`gene_expression.long.v2`）— 长表：`gene_id`, `gene_id_namespace`(Ensembl/HGNC), `gene_id_raw`, `sample_id`, `source_sample_alias`, `expression_value`(log2), `expression_unit`, `value_scale=log2`, `is_normalized=true`, `measurement_type`, `value_semantics`, 以及 `source_logical_file` / `source_line_number` / `source_column_index` / `source_column_name` / `source_raw_value` 溯源列
2. `supporting/gse15852_matrix_sample_metadata.csv` — 分组表（tumor/normal 标签）
3. `canonical/gse15852_matrix_probe_mapping.csv` — probe→gene 折叠审计（含未命中探针）
4. `schema.json` / `provenance.json` / `validation_report.json` / `confidence_records.json` / `source_coverage_report.json` + 完整 artifact sha256 清单（9 个 artifact，roles: primary_dataset, schema, provenance, 6× audit_report）

**必须如实报告的局限**
- **单数据集整合**：本次仅发布 GSE15852 一个系列。原因不是遗漏，而是被排除候选各自有硬性阻断（见上表；其中 GPL27630 缺注释表是**源侧不存在该文件**，非我可修复）。若需真正的“多系列整合”，请指定要纳入的 GSE，我会为每个 GSE 单独走一次 build（规范要求每 GSE 独立 spec/call，禁止跨 GSE 拼行）。
- **约 5.06% 探针无基因映射**（HG-U133A 平台固有，部分探针无官方 gene assignment）；这些行仍在主表中，namespace 为 `geo_probe`，做基因级差异分析时需按 `gene_id_namespace` 过滤。
- **统计异常检测器报了 2 条 warning**：Benford 首位数字 χ² 与各数字末位 χ² 超阈。这是 Affymetrix MAS5 log2 强度值的**预期分布特征**（值域集中在低位数、小数固定位数），并非数据伪造信号；我未据此删改任何记录。
- 分组标签只到 tissue group 层（tumor/normal）。GSE15852 的系列矩阵未提供分子分型/分期等额外列，故未声明这些字段；如需临床分层，需要另一来源（如 GDC/论文补充表）另行构建。
- **本轮两次失败调用如实报告**：(a) `download_geo_platform_annotation(GPL27630)` 明确返回“无可下载注释表”；(b) 一次 `workspace_exec`（bash zcat 查看表头）被权限策略拒绝（policy: rejected）——该用途本身也违反“不得用 shell 重建 provider/解析正式载体”的规则，已改用 `preview_core_asset` 完成同等检查，未重复该调用。
- 另有一次 `execute_dataset_execution` 返回 `core_execution_error`（"formal dynamic carrier lacks exact Core acquisition provenance"，标记 retryable）：原因是我把下载发现的工作区 asset 路径塞进 `source_files`。修正方式是交由 Core 自身 builtin acquisition（省略 `source_files`，仅保留单独注册的 `mapping_files`），随后一次成功。**最终发布的数据行不依赖那次的 workspace 字节**。